HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays

AIDS Research and Human Retroviruses

Volumn 16, Issue 12, 2000, Pages 1149-1156

  Robinson, L H ^a   Myers, R E ^a   Snowden, B W ^a   Tisdale, M ^a   Blair, E D ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; GAG PROTEIN; INDINAVIR; INTEGRASE; POL PROTEIN; PROTEIN P16; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRION; VIROGENESIS; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS RECOMBINANT;

ANTI-HIV AGENTS; BINDING SITES; GENE DELETION; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS; PHENOTYPE; PROVIRUSES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION;

EID: 0034632745     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200414992     Document Type: Article

References (36)

1. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
3. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
4. Viral dynamics in human immunodeficiency virus type 1 infection
5. Anti-human immunodeficiency virus drug combination strategies
6. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
7. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites
8. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
9. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
10. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
11. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro
12. The impact of PBMC co-cultivation on HIV-1 drug resistance genotypes of cultured virus relative to circulating plasma virus
13. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
14. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors
15. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
16. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
17. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
18. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
19. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
20. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
21. HIV protease inhibitors - Resistance issues
22. Human cyclophilin has a significantly higher affinity for HIV-1 recombinant p55 than p24
23. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy
24. Development of linked V32I and I47V HIV- 1 protease substitutions in some NRTI-experienced amprenavir-treated subjects
25. Clonal sequencing for detection of resistance mutations and their linkage
26. Unique resistance profile of the protease inhibitor amprenavir (141W94) observed in vitro and in the clinic
27. In vitro selection and characterization of VX-478 resistant HIV-1 variants
28. Amprenavir-resistant mutants show reduced viral fitness: Correlation of protease mutations, cleavage site mutations, enzyme kinetics, viral polyprotein processing and viral growth kinetics
29. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
30. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex
31. In vitro growth characteristics of HIV-1 variants with reduced sensitivity to saquinavir explain the appearance of L90M escape mutant in vivo
32. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
33. HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins
34. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins
35. The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins